Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Lewin-Cameron Laboratory at Doherty Institute selects OpenSpecimen system to manage biospecimens inventory

Lewin-Cameron Laboratory at Doherty Institute selects OpenSpecimen system to manage biospecimens inventory

In the short time that AXT have been promoting OpenSpecimen, the bioinformatics platform for managing biospecimens inventory developed by Krishagni Solutions in conjunction with the National Cancer Institute, it has generated large amounts of interest in Australia. [More]
Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study. [More]
Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV. [More]
Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of immunological data from the Company's clinical trials of SB-728-T, a ZFP Therapeutic designed to provide functional control of HIV. [More]
New approach to prevent mother to child transmission of HIV

New approach to prevent mother to child transmission of HIV

The first findings from a study in the Kingdom of Swaziland on a new approach to reduce mother to child transmission of HIV were presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston. [More]
Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART). [More]
ARV drug atazanavir may have significant effects on infant development

ARV drug atazanavir may have significant effects on infant development

The antiretroviral (ARV) drug atazanavir—sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy—may have small but significant effects on infant development, reports a study in the journal AIDS, official journal of the International AIDS Society. [More]
Dapivirine ring can help prevent HIV-1 infection in women

Dapivirine ring can help prevent HIV-1 infection in women

In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women. [More]
Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration. [More]
Five researchers named winners of 2016 Elsevier Foundation Awards

Five researchers named winners of 2016 Elsevier Foundation Awards

Five researchers have been named winners of the 2016 Elsevier Foundation Awards for Early Career Women Scientists in the Developing World, in recognition of research that has strong potential health and economic benefits. [More]
Researchers show how antiretroviral therapy reduces HIV infection in female reproductive tract

Researchers show how antiretroviral therapy reduces HIV infection in female reproductive tract

For the first time, investigators in the Division of Infectious Diseases at the University of North Carolina School of Medicine have determined how antiretroviral therapy (ART) affects the way HIV disseminates and establishes infection in the female reproductive tract. [More]
HIV protein alters activity of networked neurons

HIV protein alters activity of networked neurons

Nearly half of HIV infected patients suffer from impaired neurocognitive function. The HIV protein transactivator of transcription (Tat) is an important contributor to HIV neuropathogenesis because it is a potent neurotoxin that continues to be produced despite treatment with antiretroviral therapy. [More]
HIV persists in the body despite effective antiretroviral therapy

HIV persists in the body despite effective antiretroviral therapy

A team of international scientists led by Northwestern University found that HIV is still replicating in lymphoid tissue, even when it is undetectable in the blood of patients on antiretroviral drugs. [More]
Scientists demonstrate effectiveness of ART in HIV-infected infants

Scientists demonstrate effectiveness of ART in HIV-infected infants

Recent clinical trials conducted in South Africa have established that babies born with HIV should be treated with antiretroviral therapy (ART) as early as possible, since earlier treatment significantly decreases their mortality and morbidity rates. [More]
Mylan releases generic version of Felbatol Tablets in U.S.

Mylan releases generic version of Felbatol Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product. [More]

Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Adding a vaccine to the comprehensive HIV/AIDS response is essential to conclusively ending the epidemic, according to modeling research published today. [More]
Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

Mylan N.V. today announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, which is the generic version of Janssen's Ortho Tri-Cyclen Lo Tablets. [More]
Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan N.V. today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria. [More]
Single VRC01 antibody infusion could suppress HIV level in people not taking ART

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today. [More]
Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
Advertisement